Growblox Sciences, Inc. (OTCMKTS:GBLX): Designing Logistical and Retail Solutions for Cannabis


To add to our ever growing list of interesting marijuana related stocks, we’re taking a look at Growblox Sciences, Inc. (OTCMKTS:GBLX) today, a company devoted to developing cutting-edge techniques in  cannabis cultivation and by-product extraction, as well as retail distribution.

To kick off 2017, the company announced it had obtained its Nevada State Registration Certificate for a 28,000 sq. ft. cannabis cultivation facility in Las Vegas. The facility is designed to house 200 grow lights supporting roughly 800 cannabis plants, with expected yields of up to 115 pounds per month.  The company plans to eventually build out the facility to 1000 grow lights/ 4000 plants, which could generate over $20 million in revenue annually.

To go along with its cultivation efforts which should soon begin to generate revenue, Growblox Sciences, Inc. (OTCMKTS:GBLX) also has some really cool ideas with regard to retail distribution of its products, including a state-of-the-art apothecary facility along with an accompanying mobile app, as well as a secure cannabis vending machine solution.



About Growblox Sciences

Growblox Sciences, Inc. (Growblox) is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. The Company seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. Growblox intends to conduct its business operations, through its subsidiaries, in approximately three operating units, which include Solutions, Sciences and Product divisions.

  • GB Solutions

The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB.


  • GB Sciences

GB Sciences’ Drug Development program endeavors to provide novel cannabinoid therapies to patients with critically unmet needs. Starting with certified, cannabis plant-derived ingredients from the GrowBLOX™ technology suite, GB Sciences tests proprietary ratios of active ingredients in an accelerated drug development program.


  • GB Products

The GBLX line of products is the signature collection of cannabinoid therapies developed and produced by GrowBlox Sciences. Infused with certified-active ingredients derived from cannabis plants grown using the GrowBLOX system. This line of product features proprietary cannabinoid and terpenoid blends that are being extensively studied for optimal efficacy.


GB Sciences Unique Retail Solution – The Apothecary

GB Sciences has designed a unique retail environment for cannabinoid therapy providers to deliver exceptional patient care. The Apothecary by GB Sciences combines a simple, clean and clinical design with cutting edge bio-metrics and patient verification to deliver a pleasant and safe customer experience.Highly trained and certified ApotheCAREians will work with patients to determine their medical needs, identify therapeutic products, install GB Sciences’ app on their hand-held devices, and demonstrate how to place orders.

The Micro Apothecary is a self-service vending kiosk.  The interactive LED monitors display essential product and patient safety information and doubles as the touch screen interface that allows you to create a new patient profile or sign in to an existing account.

The Apothecary will have a mobile app as a powerful tool for building a strong patient- dispensary relationship.

Check out these videos outlining the features of “The Apothecary” and the proposed mobile app and read more about GBLX’s retail solutions at


We’re happy to continue adding pot plays to our radar as long as they keep cropping up, and investor sentiment remains high on cannabis! Tack GBLX onto our ever-growing list of marijuana prospects, and be sure to keep following Street Register for updates on this and many others.   Stay locked on, add us to your bookmarks, and be sure you’re signed up for our 100% free smallcap newsletter. Simply enter your primary active email address in the box below! Subscribe now!